The Canadian Registry for Pulmonary Fibrosis (CARE-PF) enrolled in its first 18 months more than 1,200 people with interstitial lung…
Articles by Marisa Wexler, MS
Delays in diagnosis and difficulty getting timely access to appropriate specialist care and treatment were highlighted as major gaps in…
Ofev (nintedanib) slows the rate of decline in lung function in people with interstitial lung diseases (ILDs) associated with…
The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and…
Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is…
Activating a dopamine receptor on fibroblast cells (connective tissue cells) may help slow, or even reverse, fibrosis in mice, a…
MN-001, a potential treatment for idiopathic pulmonary fibrosis (IPF), will soon have patent protections in China. MediciNova, the…
Esbriet (pirfenidone) shows similar benefits for people with idiopathic pulmonary fibrosis (IPF) in real-world settings as it does in…
Men who are active smokers and experience faster respiratory decline when diagnosed with idiopathic pulmonary fibrosis (IPF) are at greater…
Low body mass index (BMI) is a risk factor for nausea and diarrhea as side effects of Ofev…